U.S., Dec. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07295418) titled 'A Study of SAL003 in Participants With Hypercholesterolemia and Mixed Dyslipidemia' on Dec. 07.
Brief Summary: This is a Phase 3 study to evaluate the efficacy and safety of SAL003, a fully human monoclonal antibody against PCSK9, as monotherapy in Chinese participants with hypercholesterolemia and mixed dyslipidemia. Participants who are not on lipid-lowering therapy or have washed out from previous therapy will be randomized in a 2:1 ratio to receive either SAL003 140 mg or matching placebo, administered subcutaneously every 4 weeks for 12 weeks. Following the double-blind period, all participants will enter an open-label extensio...